Allena Pharmaceuticals, Inc. Working Capital

Working Capital of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.


Highlights and Quick Summary

  • Working Capital for the quarter ending March 31, 2022 was $10.1 Million (a -41.82% decrease compared to previous quarter)
  • Year-over-year quarterly Working Capital decreased by -50.88%
  • Annual Working Capital for 2021 was $17.3 Million (a -44.33% decrease from previous year)
  • Annual Working Capital for 2020 was $31.1 Million (a 40.67% increase from previous year)
  • Annual Working Capital for 2019 was $22.1 Million (a -62.31% decrease from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of Allena Pharmaceuticals, Inc.

Most recent Working Capitalof ALNA including historical data for past 10 years.

Interactive Chart of Working Capital of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $10.08
2021 $17.33 $34.28 $20.52 $31.76 $17.33
2020 $31.13 $27.4 $21.63 $14.74 $31.13
2019 $22.13 $31.09 $44.57 $46.3 $22.13
2018 $58.71 $67.8 $77.04 $80.1 $58.71
2017 $88.49 $27.31 $88.49
2016 $46.03
2015 $64.74 $64.74

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.